Femoston®

The drug is contraindicated for use during pregnancy and lactation (breastfeeding). If pregnancy occurs during treatment with femoston, therapy should be immediately discontinued.

The drug is prescribed to women who are in postmenopausal, only if there are symptoms that adversely affect the quality of life: "hot flashes", increased sweating, sleep disturbance, increased nervous irritability, dizziness, headache, involution of the skin and mucous membranes, especially mucous urogenital system (dryness and irritation of the vaginal mucosa, pain during intercourse).Therapy should continue as long as the benefits of taking the drug outweigh the risk of side effects, and you should strive to prescribe the minimum therapeutically effective doses of the drug. Should strive to achieve the shortest duration of treatment.
Experience with the use of the drug in women over 65 is limited.
Medical examination: Before the appointment or renewal of HRT, a complete medical and family history should be collected and a general and gynecological examination of the patient should be carried out in order to identify possible contraindications and conditions requiring compliance with precautionary measures. During treatment with Femoston 1/5 Konti, it is recommended to conduct periodic examinations, the frequency and nature of which is determined individually, but not less than 1 time per year, based on the collected history, clinical and laboratory parameters. It is advisable to conduct a study of the mammary glands, incl. mammography. Women should be informed about the possible changes in the mammary glands, which are required to inform the attending physician. The use of estrogen may affect the results of the following laboratory tests: determination of glucose tolerance, the study of the functions of the thyroid gland and liver.
Endometrial hyperplasia: for the purpose of timely diagnosis, it is advisable to conduct an ultrasound (US) screening, if necessary, to conduct a histological (cytological) study.
Bloody issues: Breakthrough bleeding and / or acyclic menstrual bleeding from the vagina may occur during the first months of drug treatment. If such bleeding occurs some time after the start of therapy or continues after cessation of treatment, their cause should be established. An endometrial biopsy may be performed to rule out a malignant neoplasm.
In the presence of thromboembolism in history Patients (including family), as well as with the usual miscarriage in history, it is necessary to conduct a study of hemostasis. Until a thorough assessment of the factors for the possible development of thromboembolism or the start of anticoagulant therapy, HRT is not applied. The risk of thrombosis of the deep veins of the lower extremities may temporarily increase with prolonged immobilization, extensive injuries or surgical interventions. If necessary, long-term immobilization after surgical interventions should stop HRT 4-6 weeks before the operation, the resumption of the drug is possible after the full restoration of the physical activity of the woman. If thrombosis develops after initiation of therapy, HRT should be abolished. You should contact your doctor if any of the symptoms indicate a possible thromboembolism (pain or swelling of the lower extremities, sudden chest pain, dyspnea, visual impairment).
Breast and ovarian cancer: in women who received long-term HRT, the frequency of diagnosis of breast cancer increases, which returns to the initial level within 5 years after discontinuation of therapy. On the background of HRT, an increase in the density of breast tissue during mammography may be observed, which may make it difficult to diagnose breast cancer. The increase in the risk of ovarian cancer with the use of estrogen drugs for HRT has not been proven.
Other states: Estrogens can cause fluid retention, which can adversely affect the condition of patients with impaired cardiac and renal function. In women with triglyceridemia in the background of HRT in very rare cases, there may be a significant increase in plasma triglyceride concentration, which contributes to the development of pancreatitis.Estrogens increase the content of thyroid-binding globulin, which leads to an overall increase in the concentration of circulating thyroid hormones (concentrations of free hormones T C and T 4 usually do not change). Levels of other serum binding proteins (corticoid binding globulin, sex hormone binding globulin) may also increase, leading to an increase in the concentration of circulating corticosteroids and sex hormones. Concentrations of free or biologically active hormones do not change. An increase in the concentration of other plasma proteins (substrate angiotensinogen / renin, a-1-antitrypsin, ceruloplasmin) is possible.

Symptoms: estradiol and didrogesteron - substances with low toxicity. No cases of overdose have been reported. Theoretically, in the case of an overdose, symptoms such as nausea, vomiting, drowsiness, and dizziness may occur.

Treatment: symptomatic.